Abstract: Provided are spray-dried thrombin powders comprising microcapsules, methods of preparation and uses thereof.

Abstract: Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.

Abstract: An absorbable iron-based alloy implantable medical device includes an iron-based alloy matrix, a degradable polymer coating disposed on the surface of the iron-based alloy matrix, and a corrosion inhibition layer disposed on the surface of the iron-based alloy matrix. The corrosion inhibition layer can delay early-stage corrosion of the iron-based alloy matrix, ensure mechanical performance of a medical device in the early stage of the implantation, prevent degradation of a polymer in the early stage of the implantation of the medical device, and reduce the usage of the degradable polymer, thereby reducing risks of inflammatory reactions.

Abstract: Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided.

Abstract: Covalently cross-linked copolymers are described herein. More specifically, polysaccharide-polyamine copolymeric matrices or structures and cationic copolymeric matrices are described herein. The polysaccharide-polyamine copolymers, when protonated, can form cationic copolymeric matrices having exceptionally high densities of cationic sites. In one form, the covalently cross-linked copolymers provide a three-dimensional structure, especially when hydrated.

Abstract: A cosmetic ink composition comprises a particulate material, a (meth)acrylic acid homopolymer or salt thereof, and a rheology modifier. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The (meth)acrylic acid homopolymer or salt thereof can have a weight average molecular weight of less than about 20,000 daltons. The rheology modifier can be selected from the group consisting of alkali swellable emulsion polymers, hydrophobically modified alkali swellable emulsion polymers, and combinations thereof. The cosmetic ink composition can have a first dynamic viscosity of greater than about 1,100 cP at a shear rate of 0.1 sec?1 measured at 25° C. and a second dynamic viscosity of less than about 100 cP at a shear rate of 1,000 sec?1 measured at 25° C.

Abstract: A process for the preparation of a composite comprising a carrier particle and a plurality of drug nanoparticles. The process comprises providing a suspension of drug nanoparticles in the presence of a carrier particle, the carrier particle having an external surface that is functionalised with a surface treatment agent. The process simplifies isolation of drug nanoparticles from suspension.

Abstract: Non-viral delivery platforms are provided for facilitating transport of molecules across cell membranes. In some forms, DNA nanoshells capable of transporting cargo molecules are formed, and may be formed in order to surround a variety of materials for a variety of purposes.

Abstract: A nanoparticle suitable for delivery of an active agent across the blood-brain barrier is provided. As such, the nanoparticle can target brain tissue so that the active agent can be delivered across the blood-brain barrier to the target brain tissue. The nanoparticle includes a core that includes a core material such as a polymer or inorganic material as well as an active agent; and a shell comprising a membrane derived from a brain metastatic cancer cell, wherein the brain metastatic cancer cell facilitates transport of the nanoparticle across a blood-brain barrier. Also disclosed are methods of forming the nanoparticle and methods of using the nanoparticle.

Abstract: Described herein are hydrolyzed tetravalent salts and formulations thereof that can be used to inhibit a biofilm. Also described herein are uses of the hydrolyzed tetravalent salts and formulations thereof to inhibit a biofilm and/or treat biofilm infection.

Abstract: Melts or ionic liquids containing amorphous propranolol, topical formulations and patches for transdermal drug delivery, and methods of making and using thereof are described herein. The melts or ionic liquids may be in a topical drug delivery formulation or patch to be applied to the skin. The drug delivery formulation or patch contains a sufficient amount of the amorphous propranolol to deliver a therapeutically effective amount of the amorphous propranolol to the patient in need of treatment, such as for the treatment or amelioration of infantile hemangioma. The formulations have a low viscosity and reduced skin irritation compared to the crystalline propranolol free base (PFB). The melts or ionic liquids can be formed by a salt metathesis reaction.

Abstract: A method of making at least one nanocomposite for surface enhanced Raman spectroscopy (SERS) detection of a target of interest includes forming at least one gold nanorod; coating a silver layer on an outer surface of the gold nanorod; assembling a Raman reporter molecule layer on the coated silver layer, wherein the Raman reporter molecule layer comprises Raman reporter molecules that are detectable by the SERS; coating a thiolated polyethylene glycol (PEG) layer on the assembled Raman reporter molecule layer; and conjugating the coated thiolated PEG layer with molecules of an antibody to make the at least one nanocomposite.

Abstract: A cosmetic ink composition comprises a particulate material, a polymeric dispersant having a weight average molecular weight of less than about 20,000 daltons, and a polymeric rheology modifier. The particulate material can have a Particle Size Distribution D50 of about 100 nm to about 2,000 nm. The cosmetic ink composition can undergo controlled syneresis, forming a weak colloidal gel phase and a particle-lean, low viscosity phase, which can be printed without interventions such as agitation, mixing, or re-circulation to homogenize the composition.

Abstract: A drug-impregnated sleeve for encasing a medical implant is provided. In one embodiment, the sleeve may include a body made of a biologically-compatible material that defines an internal cavity configured to receive the medical implant. In one embodiment, the biologically-compatible material is bioresorbable. The body may include a plurality of apertures, such as perforations or holes, extending from the cavity through the body. The sleeve may further include a first end, a second end, and a drug impregnated into the resorbable sheet. In one possible embodiment, the first end of the sleeve may be open for receiving the medical implant therethrough and the second end may be closed. The implant may be encased in the sleeve and implanted into a patient from which the drug is dispensed in vivo over time to tissue surrounding the implantation site. In one embodiment, the body is made from at least one sheet of a biologically-compatible material.

Abstract: The present invention relates to a tableted chewing gum composition for oral administration of cannabinoids, the composition comprising a plurality of particles, including a first population of particles comprising water-insoluble gum base and a second population of particles comprising water-soluble chewing gum ingredients, and the composition constituting at least two layers, wherein a first layer of the composition comprises water-insoluble gum base and a second layer of the composition, which is cohered to and adjacent to the first layer, comprises water-soluble chewing gum ingredients, the second layer being free of water-insoluble gum base, and wherein the composition comprises one or more cannabinoids.

Abstract: A composition comprising a nanoparticle, wherein the nanoparticle comprises a polymer/copolymer conjugated to a moiety is disclosed. A method of forming a nanostructure includes stirring poly(lactide-co-glycolide (PLGA) and 11-Ethyl-3-(dimethylaminopropyl) carbodiimide (EDC) in CH2Cl2 to create a PLGA mixture, n-boc-ethyelenediamine and N,N-Diisopropylethylamine (DIEA) are added to the PLGA mixture to create a reaction mixture. The reaction mixture is then precipitated in cold diethyl ether to form a purified polymer, which is then dried. The dried and purified polymer is then reconstituted in CH2Cl2:TFA solution and stirred under inert conditions. The product of the reconstituting step is evaporated to form a clear viscous residue that is dissolved in CH2Cl2 and then precipitated in cold ether to form a polymer. These functional polymers can encapsulate a variety of bioactives forming nanosystems improving the performance of bioactives.

Abstract: Implantable materials may be used in an iatrogenic site. Applications include radioopaque materials for fiducial marking.

Abstract: The present invention provides methods and compositions for the remote control of cell function based on the use of radiofrequency waves to excite nanoparticles targeted to specific cell types. The nanoparticles may be applied to the target cell extracellularly and/or expressed intracellularly. The cell type of interest expresses a temperature sensitive channel wherein excitation of the nanoparticles results in a localized temperature increase that is transduced into a cellular response. Such cellular responses may include, for example, increases in gene expression resulting in production of one or more physiologically active proteins. The expression of such proteins can be used to treat a variety of different inherited or acquired diseases or disorders in a subject. Accordingly, the invention provides a generic approach for treatment of any disease associated with a protein deficiency.

Abstract: The invention provides devices and methods for adjusting particle size in nanoemulsions of fluorocarbons and perfluorocarbons (e.g., perfluoropentane and perfluorohexane) via sonication (e.g., ultrasonication).

Abstract: The invention relates to pharmaceutical compositions in liquid form comprising pradofloxacin in an aqueous solution and citric acid or thioglycerol as antioxidants.